|
Aug 4
|
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
|
|
Aug 4
|
Will These 5 Pharma, Biotech Bigwigs Surpass Q2 Earnings Forecasts?
|
|
Aug 4
|
Arrowhead sells China hypertriglyceridemia candidate rights to Sanofi
|
|
Aug 1
|
Health Care Roundup: Market Talk
|
|
Aug 1
|
Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
|
|
Aug 1
|
Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping.
|
|
Aug 1
|
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
|
|
Aug 1
|
Regeneron posts better-than-expected Q2 results, downplays tariff impact
|
|
Aug 1
|
Reddit, Coinbase, Novo Nordisk - Trending Stocks
|
|
Aug 1
|
Regeneron shares edge higher as second quarter earnings surpass estimates
|
|
Aug 1
|
Regeneron Reports Second Quarter 2025 Financial and Operating Results
|
|
Aug 1
|
Arrowhead Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi
|
|
Aug 1
|
European drugmakers fall after Trump raises stakes over US drug price cuts
|
|
Jul 31
|
What Trump's Big Pharma CEO letters mean for drug pricing power
|
|
Jul 31
|
Trump Sends Letters to 17 Pharmaceutical Companies Asking Them to Lower Costs
|
|
Jul 31
|
Trump pressures 17 pharma CEOs to cut US drug prices
|
|
Jul 31
|
Dupixent sales spur Sanofi growth, but profits fall short
|
|
Jul 31
|
Press release: Online availability of Sanofi’s half-year financial report for 2025
|
|
Jul 31
|
European Equities Traded in the US as American Depositary Receipts Falling Thursday
|
|
Jul 31
|
Sanofi Q2 Earnings & Sales Miss, 2025 Top-Line View Raised, Stock Down
|